首页 › 基金 › Callodine Capital Management, LP › GSK

Callodine Capital Management, LP 对 GSK 的持仓历史

GSK PLC · 医疗保健

Callodine Capital Management, LP 在 Q3 2026 的 13F 申报中披露持有 GSK(GSK PLC)1,047,359 股,市值约 US$50.5M,约占其申报组合的 3.23%,在其申报持仓中市值排名第 8 位。 Callodine Capital Management, LP 最近 13 个申报季度中有 13 个季度披露了 GSK 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q3 2026)1.05M 股
申报持仓市值$50.45M
组合权重3.23%
首次申报Q3 2023
最近变动增持
更新于2026-11-13

最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR

Callodine Capital Management, LP 对 GSK 的持仓演变

Callodine Capital Management, LP 于 Q3 2023 首次披露 GSK 持仓:475,000 股(约 US$17.2M)。 该持仓在 Q1 2026 达到峰值 1,259,477 股,市值约 US$69.5M。 在 13 次申报中,Callodine Capital Management, LP 8 次增持、4 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 1,047,359 股、市值约 US$50.5M,环比增持 67,619 股。。 持仓曾出现大幅变动:Q2 2024 增持约 35% (随后一个季度股价上涨 6%)、Q4 2025 增持约 43% (随后一个季度股价上涨 13%)、Q1 2026 增持约 25% (随后一个季度股价下跌 5%)。

逐季持仓明细

季度股数金额变化
Q3 2023 475.00K $17.22M 新进
Q4 2023 450.00K $16.68M 减持
Q1 2024 400.00K $17.15M 减持
Q2 2024 540.00K $20.79M 增持
Q3 2024 605.00K $24.73M 增持
Q4 2024 700.00K $23.67M 增持
Q1 2025 570.00K $22.08M 减持
Q2 2025 598.52K $22.98M 增持
Q3 2025 702.05K $30.30M 增持
Q4 2025 1.00M $49.25M 增持
Q1 2026 1.26M $69.51M 增持
Q2 2026 979.74K $51.36M 减持
Q3 2026 1.05M $50.45M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 GSK 与 13F 数据

GSK(GSK PLC)属于医疗保健行业。我们追踪的基金中还有 20 只申报持有 GSK,申报仓位最大的包括:Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 GSK 的基金

查看 GSK 的全部基金持有人 →

常见问题

How long has Callodine Capital Management, LP held GSK?

Callodine Capital Management, LP has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Callodine Capital Management, LP's current position in GSK?

As of Q3 2026, Callodine Capital Management, LP holds 1.05M shares of GSK (GSK PLC), valued at $50.45M, representing 3.23% of its reported portfolio and ranking #8.

Has Callodine Capital Management, LP been buying or selling GSK?

In the latest 13F filing (Q3 2026), Callodine Capital Management, LP increased its position in GSK. The position peaked in Q1 2026 at 1.26M shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.